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Abstract
Excessive use of antibiotics, especially watch group antibiotics such as ceftriaxone leads to
emergence and spread of antimicrobial resistance (AMR). In low and middle-income coun-
tries (LMICs), antibiotics are overused but data on consumption is scarcely available. We
aimed at determining the extent and predictors of ceftriaxone use in a tertiary care university
teaching hospital in Kilimanjaro, Tanzania. A hospital-based cross-sectional study was con-
ducted from August 2013 through August 2015. Patients admitted in the medical, surgical
wards and their respective intensive care units, receiving antimicrobials and other medica-
tions for various ailments were enrolled. Socio-demographic and clinical data were recorded
in a structured questionnaire from patients’ files and logistic regression was performed to
determine the predictors for ceftriaxone use. Out of the 630 patients included in this study,
322 (51.1%) patients were on ceftriaxone during their time of hospitalization. Twenty-two
patients out of 320 (6.9%) had been on ceftriaxone treatment without evidence of infection.
Ceftriaxone use for surgical prophylaxis was 44 (40.7%), of which 32 (72.7%) and 9 (20.5%)
received ceftriaxone prophylaxis before and after surgery, respectively. Three (6.8%)
received ceftriaxone prophylaxis during surgery. Predicting factors for that the health facility
administered ceftriaxone were identified as history of any medication use before referral to
hospital [OR = 3.4, 95% CI (1.0–11.4), p = 0.047], bacterial infection [OR = 18.0, 95% CI
(1.4–225.7, p = 0.025)], surgical ward [OR = 2.9, 95% CI (0.9–9.4), p = 0.078] and medical
wards [OR = 5.0, 95% CI (0.9–28.3), p = 0.070]. Overall, a high ceftriaxone use at KCMC
hospital was observed. Antimicrobial stewardship programs are highly needed to monitor
and regulate hospital antimicrobial consumption, which in turn could help in halting the rising
crisis of antimicrobial resistance.
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Introduction
Ceftriaxone is a third generation cephalosporin antibiotic. It is among a group of broad-spec-
trum antibiotics covering a wide range of infections. It is used as a first choice for acute bacte-
rial meningitis, community acquired pneumonia (severe), complicated intra-abdominal
infections (mild to moderate), complicated intra-abdominal infections (severe), hospital
acquired pneumonia, Neisseria gonorrhoeae, pyelonephritis or prostatitis (severe). It is used as
second choice for acute invasive bacterial diarrhoea / dysentery, bone and joint infections,
pyelonephritis or prostatitis (mild to moderate), sepsis in neonates and children. [1,2].
In Tanzania, as in many other countries, ceftriaxone is as well among the “watch group”
antibiotics[3–5]. Cephalosporins should only be prescribed when there is evidence of infection
such as increase in serum procalcitonin levels or bacterial culture and sensitivity results from
the clinical laboratory. However, ceftriaxone has often inappropriately and excessively been
prescribed in clinical settings especially where there is lack of clear diagnosis[6,7]. Although
ceftriaxone can be used as prophylaxis in certain situations, in a National Hospital in Tanzania,
ceftriaxone was the most given prophylactic antibiotic regardless of the urological surgery
done and its level of contamination[8]. The impact of irrational use of ceftriaxone on develop-
ment of resistance to third-generation cephalosporins among clinical strains of Enterobacteria-
cea and other non- enteric bacteria is well known[9–11] and is one of the emerging global
public health issues, particularly in LMICs [7,12]. This has furthermore lead the World Health
Organization (WHO) to call for optimization of antimicrobial use to curb AMR [13]. If resis-
tance to ceftriaxone is becoming widespread, not only are very few alternative antibiotic
options available in LMICs like Tanzania, but these few options are as well unaffordable by the
majority patients.
Unfortunately, resistance to third generation cephalosporins is already very high. For
instance, in one review on AMR covering Eastern African countries the proportion of Gram
negative and positive bacteria that were resistant to ceftriaxone was ranging from 46–96% and
50–100%, respectively[14]. In northwestern Tanzania, resistance to ceftriaxone was 29.4% in
2010[15] and 35% (in 2014) regarding resistance to carbapenems[16]. Furthermore, a study
from Mwanza, Tanzania observed that 25 (80.6%) of Klebsiella pneumoniae were cephalospo-
rin resistant and overall increase in resistant isolates to third-generation cephalosporins rose
from 26.5% in 2014 to 57.9% in 2015 [17]. Another study from a tertiary care, university teach-
ing hospital in Mwanza, Tanzania had previously revealed an increasing trend of bacterial
resistance against ceftriaxone from 14% in 2009 to 29.4% in 2011[15]. In a 2013–2015 study at
a tertiary care hospital in Kilimanjaro the reported resistance to ceftriaxone by Gram-negative
bacteria among in-patients was 51.8% [18]. In East Africa, including Tanzania, there is a pau-
city of timely data on antibiotic consumption especially on ceftriaxone use in hospitals[14,19].
Therefore, the present study aimed at identifying the extent of ceftriaxone use and determining
predictors of ceftriaxone use at a tertiary care and a university teaching hospital in Kilimanjaro
Tanzania.
Materials and methods
Ethical approval and participant’s consent
This study was granted ethical approval by the KCMC Research Ethics Committee and the
National Institute for Medical Research with approval numbers 893 and NIMR/HQ/R.8a/Vol.
IX/2080 respectively. A written informed consent was obtained from each participant or from
parents or guardians of children before enrolment into the study.
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Study settings and design
A cross-sectional study was carried out from August 2013 through August 2015 at Kilimanjaro
Christian Medical Centre (KCMC). KCMC is a consultant, tertiary care and a referral hospital
located in Moshi municipality. It has a 650-bed capacity and the second largest consultant
referral university teaching hospital serving over 12 million people from northern and central
regions of Tanzania (http://www.kcmc.ac.tz/). The study involved inpatients. All admitted
patients in medical and surgical wards and their respective Intensive Care Units who had a
documented presumptive diagnosis of septicaemia and upper respiratory tract infection were
enrolled. Also enrolled were those patients with diarrhoea, diabetic ulcer, patients with fever of
unknown cause, wounds due to burns, surgical procedures, diabetes mellitus, animal bites,
motor traffic accidents and other injuries. The study was granted ethical approval by the
KCMC Research Ethics Committee and the National Institute for Medical Research. A written
informed consent was obtained from each participant or from parents or guardians of children
before enrollment into the study.
Data abstraction and analysis
Data were extracted from patient files among all inpatients in medical and surgical wards with
a presumptive diagnosis of a bacterial infection. Data collected include type of ward, use of cef-
triaxone or any other antibiotics, clinical diagnoses and socio-demographics. All data were
recorded in a structured questionnaire and double entered in OpenClinica (OpenClinica LLC,
MA, USA). Data were cleaned and analyzed using Stata 13 (StataCorp LP, Texas 77845, USA).
The proportion of ceftriaxone use was determined by dividing the number of patients taking
ceftriaxone by the total number of patients who had a presumptive diagnosis of a bacterial
infection. The prevalence of ceftriaxone use across categorical variables (such as gender, timing
of prophylaxis, presence of infection, diagnoses, number of days of hospital stay et cetera) was
compared using Chi-square or Fisher’s exact tests. Bivariate and adjusted logistic regression
analyses were used to determine possible factors that were associated with ceftriaxone use.
Both forward selection and backward elimination model building approaches were performed
and were both found to predict the same final model. Statistical significance was set at cut off
points of 0.20 and 0.10 for bivariate and adjusted analyses respectively.
Results
Study population characteristics
The study population included patients admitted in the wards of KCMC as previously
described by Kumburu et al[18]. A total of 630 patients were included in analysis, of which
males were 360 (59.1%), 343 (58.8%) were married and 256 (42.6%) were aged 19–45 years.
Those with primary education were 359 (62.1%), farmers were 290 (49.2%) and who had
stayed in hospital for a week or less were 393 (64.0%) (Table 1).
Prevalence of ceftriaxone use
Out of the 630 patients, 322 patients (51.1%) were on ceftriaxone during their time of hospital-
ization. Out of 108 patients who underwent surgery, 44 (40.7%) received ceftriaxone for surgi-
cal prophylaxis. Ceftriaxone prophylaxis before and after surgery was given in 32 (72.7%) and
9 (20.5%) patients, respectively. Three (6.8%) received ceftriaxone prophylaxis during surgery.
Twenty-two (6.9%) of the patients received ceftriaxone treatment without having any infection
as determined clinically. A total of 166 patients (51.5%) with wounds received ceftriaxone as
treatment of choice. 126 (39.8%) and 81 (25.6%) of patients admitted in surgical and medical
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wards, respectively received ceftriaxone during their treatment. The possible association
between period admitted at hospital and ceftriaxone use was evaluated: Among patients
with� 7 days admitted, 195 (61.9%) were on ceftriaxone, while patients admitted for 8–14
days it was 66 (21.0%) and patients admitted for more than 14 days it was 54 (17.1%) (Table 2).
Factors predicting ceftriaxone use among inpatients at KCMC hospital
Bivariate and multivariable regression analyses were performed to identify predictors of ceftri-
axone use in KCMC hospital. Significant predictors of ceftriaxone use on a bivariate level
were: transfer from another hospital [OR = 1.9, 95% CI (1.3–2.6), p = 0.000], all wound types
[OR = 1.7, 95% CI (1.3–2.4), p = 0.001], seeking or looking for any medical service before com-
ing to hospital [OR = 1.7, 95% CI (1.2–2.5), p = 0.006], history of medication use before com-
ing to hospital [OR = 2.5, 95% CI (1.7–3.8), p = 0.000], the patient having any bacterial
Table 1. Study population characteristics.
Characteristics n (%)
Age group (years)
< = 18 76 (12.1)
19–45 256 (40.6)
46–65 182 (28.9)
66+ 87 (13.8)
Missing 29 (4.6)
Gender
Female 249 (39.5)
Male 360 (57.2)
Missing 21 (3.3)
Education
No formal education 108 (17.2)
Primary 359 (57.0)
Secondary 74 (11.6)
Tertiary 37 (5.9)
Missing 52 (8.3)
Marital status
Single 168 (26.7)
Married 343 (54.4)
Widowed 47 (7.5)
Divorced 25 (3.4)
Missing 47 (7.5)
Occupation
Peasantry 290 (46.0)
Employed 59 (09.4)
Business 125 (19.8)
Others 116 (18.4.)
Missing 40 (6.4)
Hospital stay (days)
�7 393 (62.4)
8–14 105 (16.7)
�14 116 (18.4)
Missing 16 (2.5)
https://doi.org/10.1371/journal.pone.0220261.t001
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Table 2. Ceftriaxone use among inpatients at KCMC hospital.
Characteristic n (%) χ2 p
Over all 322 (51.1)
Gender
Female 137 (43.2) 1.48 0.223
Male 180 (56.8)
Surgical Prophylaxis
Before surgery 32 (72.7) 6.02 0.049
During surgery 3 (6.8)
After surgery 9 (20.5)
Infection present
No 22 (6.9) 5.89 0.015
Yes 298 (93.1)
Diagnoses
cellulitis
No 308 (95.7) 5.27 0.022
Yes 14 (4.3)
cough
No 318 (98.8) 0.004 0.95
Yes 4 (1.2)
diabetes
No 286 (88.8) 5.72 0.017
Yes 36 (11.2)
wound
No 156 (48.4) 11.15 0.001
Yes 166 (51.5)
meningitis
No 317 (98.4) 2.59 0.107
Yes 5 (1.6)
diarrhoea
No 318 (98.7) 7.08
Yes 4 (1.3)
septicaemia
No 294 (91.3) 2.97 0.085
Yes 28 (8.7)
pneumonia
No 286 (88.8) 0.2 0.652
Yes 36 (11.2)
Ward type
Surgical1
No 191(60.2) 10 0.002
Yes 126 (39.8)
Surgical2
No 306 (96.5) 0.28 0.597
Yes 11 (3.5)
Surgical ICU
No 300 (94.6) 2.21 0.137
Yes 17 (5.4)
Medical 1
(Continued)
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infection [OR = 2.0, 95% CI (1.1–3.4), p = 0.017], the patient being under any medication
[OR = 14.4, 95% CI (1.9–110.7), p = 0.011], septic infected burn wound [OR = 1.8, 95% CI
(1.0–3.2), p = 0.041], diarrhoea [OR = 0.3, 95% CI (0.1–0.8), p = 0.014] and surgical 1 ward
[OR = 1.7, 95% CI (1.2–2.4), p = 0.002]. Factors that were significantly associated with ceftriax-
one use after adjusting for other factors include history of medication use before coming to
hospital [OR = 3.4, 95% CI (1.0–11.1), p = 0.047], the patient having any bacterial infection
[OR = 18, 95% CI (1.4–225.7), p = 0.025], Surgical ward 2 [OR = 2.9, 95% CI (0.9–9.4),
p = 0.078] and Medical ward 1 [OR = 5.0, 95% CI (0.9–28.3), p = 0.070] (Fig 1)
Discussion
This study was carried out to investigate ceftriaxone use among inpatients in a tertiary care
university teaching hospital in Kilimanjaro, Tanzania. The overall use of ceftriaxone among
inpatients in this study was high (51.1%). Ceftriaxone is among the most commonly utilized
antibiotics owing to its high potency, a wide spectrum of activity, and a low risk of toxicity[5].
It is used to treat different types of bacterial infections including pneumonia, bone, abdominal,
skin and soft tissue, and urinary tract [5][20]. It has an advantage of a wide coverage of patho-
gens, easy administration as it is once daily dosing–limiting nursing time needed and a low
cost compared to many antibiotics.[21] [22][23] Other studies have as well shown a relatively
similar extent of use to the current study; for instance, in a study from a tertiary care hospital
in Dar es Salaam where ceftriaxone use as urological surgical prophylaxis was 46.1% [8] and in
Nigeria ceftriaxone use for a suspected systemic infection was 42.3% [24] and even higher use
in Ethiopia empiric ceftriaxone use was 58% [25] presumptive diagnoses of pneumonia, men-
ingitis and sepsis led to ceftriaxone use in 59.3% [12] and the utilization rate of ceftriaxone was
found to be high with a point prevalence of 59% where ceftriaxone was empirically used in
79.5% of cases [5]. Thus, generally, the observed ceftriaxone use in the present study as is in
other studies is irrationally high as this drug (and as well, other cephalosporins) should only be
used as a life saving drug against confirmed severe infections and not prescribed routinely.
Another indication for cephalosporins should be in confirmed resistance to first and second
line antibiotics. Nonchalant ceftriaxone prescription habits by Tanzanian clinicians has been
Table 2. (Continued)
Characteristic n (%) χ2 p
No 236 (74.4) 2.03 0.154
Yes 81 (25.6)
Medical 2
No 260 (82.0) 1.18 0.277
Yes 57 (18.0)
Medical ICU
No 298 (94.0) 4.18 0.041
Yes 19 (6.0)
Other wards
No 311 (98.1) 19.2 0
Yes 6 (1.9)
Hospital stay (days)
� 7 195 (61.9) 7.1 0.029
01/08/14 66 (21.0)
Above 14 54 (17.1)
https://doi.org/10.1371/journal.pone.0220261.t002
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observed to be a common practice in many clinical settings[8] which warrants immediate
intervention through antimicrobial stewardship that can monitor adherence to prescription
guidelines.
In suspected infection clinicians are not entirely sure if the offending organism is a bacte-
rium. Other causes of fever may be viruses and fungi or even dehydration. In some circum-
stances it is advised to not use any antibiotic as the causative organism could be a virus[26].
Alternatives to ceftriaxone that should be suggested instead include fortified penicillin such as
amoxicillin clavulanate; macrolides like azithromycin; and aminoglycosides like gentamicin
depending on the offending bacteria infection [27].
In the present study, ceftriaxone use for surgical prophylaxis was 40.7% and importantly,
out of these, 20.5% received ceftriaxone prophylaxis after surgery. This is a prolonged antibi-
otic prophylaxis constituting an unnecessarily excessive antibiotic exposure, which is an
important driver of AMR emergence and spread. Similar observations were seen from the
Fig 1. A forest plot to show univariable and multivariable regression analysis on factors predicting ceftriaxone use. Referral (Transferred from another
hospital), Medication (Patient on any medication), Wound (Any wound, including septic infected burn wound), Previous admission (Previous admission to
hospital), Prior medical service (Any medical service before coming to hospital), Hospital stay (Length of hospital stay in days), Surgical ward 2 (Department of
surgery ward 2), Medical ward 1 (Department of Medicine ward 2), Current Infection (A Presumptive diagnosis of infection present at admission).
https://doi.org/10.1371/journal.pone.0220261.g001
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hospital in Dar es Salaam regarding use of ceftriaxone for prophylaxis where 86.4% of patients
were put on post operative ceftriaxone prophylaxis for up to five days in the majority of elec-
tive, clean surgeries[8] and for surgeries involving thyroidectomy (58.2%) and cystectomy
(47.8%) [28]. Prolonged surgical ceftriaxone prophylaxes are also observed in a tertiary care
hospital in Ethiopia where (94%) had post operative prophylaxis and (70%) used ceftriaxone
[29]. Again in Ethiopia ceftriaxone surgical prophylaxis was (84.5%)[30]. The absence of local
surgical prophylactic guidelines was identified to be the cause of excessive ceftriaxone adminis-
tration. Other documented causes are absence of first and second generation cephalosporins,
low cost of ceftriaxone, absence of microbiologic data to inform both prophylactic and empiric
antibiotic practice and lack of evidence based protocol for the settings where ceftriaxone are
over administered[29]. Intuitively, some clean surgeries do not even need antibiotic prophy-
laxes. Alternative agents to ceftriaxone prophylaxis, according to The Scottish Intercollegiate
Guidelines Network (SIGN) guidelines, depending on surgery types are penicillins e.g. benzyl-
penicillin for suspected streptococci, N. meningitidis, and spirochaetes; Aminoglycosides e.g.
gentamicin mostly for suspected Gram-negative bacteria including Pseudomonas; Macrolides
e.g. azithromycin for suspected Gram-positive bacteria and some Gram-negative bacteria
(Haemophilus, Neisseria, Moraxella), has an important activity against intracellular bacteria
including Chlamydia, Legionella, Mycoplasma species and to patients allergic to beta lactams;
Fluoroquinolones e.g. ciprofloxacin for suspected Gram positive and Gram-negative bacteria
including Pseudomonas; Nitroimidazoles e.g. metronidazole for suspected anaerobes[27].
The present study as well documents a low level (6.9%) of ceftriaxone use without evidence
of infection (empiric treatment) which is much lower compared to a study in Uganda with a
77.7% empiric ceftriaxone use among children suspected of central nervous system infection
[31]. One might argue that the central nervous system infection may be quite severe and other
antibiotics might be resistant in Ugandan children, hence the choice of ceftriaxone. Other
studies in Ethiopia indicated ceftriaxone empiric treatment to range between 79.0–87.3%
[5,25]. While such ceftriaxone prescribing practices may be life saving, a need arises to be
guided by locally generated data on sensitivity patterns[32–35]. To rationalize antimicrobial
consumption and mitigate rapid development of AMR, hospital antimicrobial stewardship
programs should impose and enforce prescription restrictions, set up antibiotic consumption
surveillance systems and deliver appropriate educational campaigns to prescribers. Steward-
ship will as well increase knowledge on resistance patterns to secure other low spectrum antibi-
otics that can still be effectively used. There is evidence showing a significant reduction in
ceftriaxone use from 72% to 21% after the introduction of clinical practice guideline in a ter-
tiary care pediatric hospital in Kansas city, Missouri, USA[36].
In the present study we further investigated factors that may be associated with the health
facility administering ceftriaxone. Factors that were significant predictors of ceftriaxone
administration included history of prior medication before admission to this hospital, patient
having bacterial infection, being in surgical and medical wards. Patients with previous antibi-
otic use from another hospital were more likely to be provided with ceftriaxone by the health
facility[37] possibly due to the fact that clinicians might have thought that the referred patients
had to be put on a broad-spectrum regimen like ceftriaxone to cover for bacteria that might
have resisted in the previous antibiotic exposure [38]. Patients having a presumptive diagnosis
of bacterial infection significantly predicted ceftriaxone use. The reason could be that unavail-
ability and inaccessibility to microbiological tests influence clinicians to use broad spectrum
antibiotics to suppress infection and hence avoid prolonged illness[39].
Type of wards the patient was admitted in appeared to be associated with ceftriaxone use.
Surgical 2 and Medical 1 wards are used for admissions for referral and new cases respectively.
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Surgical 2 ward usually admits postoperative patients; the fact that may explain the observed
significant ceftriaxone administration.
A strength in the present study is that data were collected from a consultant and a tertiary
care facility. This could imply and depict the real practice in many tertiary hospitals in Tanza-
nia. However, we acknowledge inherent weaknesses of this study in that first, we could not
ascertain treatment outcomes. Second, the data were strictly on the clinical acumen of the cli-
nicians in deciding to prescribe ceftriaxone. Third, a poor documentation of the dosages and
duration of ceftriaxone use in the patients’ files rendered it cumbersome for us to calculate the
(Prescribed Daily Doses (PDDs) or (Defined Daily Doses (DDDs) which would have showed
the volumes of ceftriaxone consumed. Third, there are other factors that come into play that
this study could not investigate. These include a clinician prescription, pharmaceutical compa-
nies and health insurance companies’ influence. This could be an avenue for further study to
explore the contribution of these factors and others toward excessive use of antibiotics in
Tanzania.
Conclusions
Ceftriaxone is extensively used in this hospital. We have observed inappropriately prolonged
ceftriaxone surgical prophylaxis practice, empiric treatment with ceftriaxone particularly
wound treatment with ceftriaxone without culture and sensitivity results. We recommend an
antibiotic stewardship team to be instituted to constantly identify areas of improvement for
optimal antibiotic use in general. The antibiotic stewardship team will also be instrumental to
strike a balance between restricting antibiotic use to minimize antibiotic resistance, whilst
allowing antimicrobial use where appropriate.
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